SynthesisMedical mycology2024
Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.
Synthesis in Medical mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Captive lizards (Squamata: Sauria) as reservoirs of medically important and antifungal-resistant yeasts.Medical mycology · 2026Article
- First Case of Candidemia Caused by Fluconazole-Resistant Candida orthopsilosis Harboring the ERG11 G458S Mutation in a Hematopoietic Stem Cell Transplant Recipient in Asia.Mycopathologia · 2026Article
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- IFUCISTRATEGY: A Spanish Survey on the Management of Invasive Fungal Infection (IFI) in Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2026Article
- Non-AlbicansInfectious disease reports · 2026Review
- Tolerance of outbreak-associated Candida parapsilosis isolates to antiseptics in a dry surface biofilm model.Scientific reports · 2026Article
- Azole Resistance in Candida parapsilosis From Patients With Burns in Mexico: A Genomic and Phylogenetic Analysis.Mycoses · 2026Article
- In vitro activity of eight antifungal drugs against clinical and hospital isolates of Candida parapsilosis complex; a multicenter study, 2023-2024.BMC infectious diseases · 2026Article
- Persistence and spread of fluconazole-resistantMicrobial genomics · 2026Article
- Non-Life (Basel, Switzerland) · 2026Article
- Catechin Augments the Antifungal Efficacy of Fluconazole AgainstInternational journal of molecular sciences · 2026Article
- Unveiling the diversity, ecology, and biotechnological potential of culturable marine yeasts in Western Mediterranean coastal ecosystems.IMA fungus · 2026Article
- Candidemia in a tertiary hospital in Southern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Biofilm-related characteristics ofFrontiers in cellular and infection microbiology · 2026Article
- Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.npj antimicrobials and resistance · 2025Review
- Silent Persistence: Molecular Evidence of Clonal Transmission in Fluconazole-ResistantJournal of fungi (Basel, Switzerland) · 2025Article
- Fungal Prosthetic Joint Infection byAntibiotics (Basel, Switzerland) · 2025Article
- Clinical impact of fluconazole-resistantFuture microbiology · 2025Review
- Clinical Utility of the T2Candida Panel: A Real-World Analysis of More Than 2000 Cases.Mycopathologia · 2025Article
- Antimicrobial Resistance in Sub-Saharan Africa: A Comprehensive Landscape Review.The American journal of tropical medicine and hygiene · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Candida parapsilosis is globally distributed and recognised for causing an increasing proportion of invasive Candida infections. It is associated with high crude mortality in all age groups. It has been particularly associated with nosocomial outbreaks, particularly in association with the use of invasive medical devices such as central venous catheters. Candida parapsilosis is one of the pathogens considered in the WHO priority pathogens list, and this review was conducted to inform the ranking of the pathogen in the list. In this systematic review, we searched PubMed and Web of Science to find studies between 2011 and 2021 reporting on the following criteria for C. parapsilosis infections: mortality, morbidity (hospitalisation and disability), drug resistance, preventability, yearly incidence, and distribution/emergence. We identified 336 potentially relevant papers, of which 51 were included in the analyses. The included studies confirmed high mortality rates, ranging from 17.5% to 46.8%. Data on disability and sequelae were sparse. Many reports highlighted concerns with azole resistance, with resistance rates of >10% described in some regions. Annual incidence rates were relatively poorly described, although there was clear evidence that the proportion of candidaemia cases caused by C. parapsilosis increased over time. While this review summarises current data on C.parapsilosis, there remains an urgent need for ongoing research and surveillance to fully understand and manage this increasingly important pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.